BNET Industries

Repligen Corp.

(RGEN) is in the Pharma Industry

Market Cap:$116.5M
Last Fiscal Year Sales:$19.2M
  • Public
  • US
Dow Jones Description

Novel Therapeutics Developer

President, Chief Executive Officer and Director
Walter C. Herlihy
Number of Employees 69
Contact Information

41 Sayon St Bldg 1 Ste 100

Waltham, Massachusetts 02453

repligen.com

1 781 250 0111

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical...

    12/16/09 - New Investment - View Story

  • Repligen Reports Second Quarter Fiscal Year 2010 Financial Results

    11/08/09 - Financial Announcement - View Story

  • Repligen RGEN Downgrade Alert, Watch for 0.1% Technical Downtrend Continuation

    10/29/09 - Bond / Stock Rating - View Story

  • Repligen signs licensing agreement with FSMA

    10/23/09 - Joint Venture / Alliance - View Story

  • Repligen Licenses Potential Treatment for Spinal Muscular Atrophy

    10/28/09 - Joint Venture / Alliance - View Story

  • Repligen Appoints Glenn Cooper, M.D. to Its Board

    8/30/09 - Board Member - Entering - View Story

  • Repligen reports Q1 net loss

    8/11/09 - Financial Announcement - View Story

News & Analysis

repligen corp. - All News and Analysis

Decision Makers

Name (plus bio) Position
Walter C. Herlihy President, Chief Executive Officer and Director
Daniel W. Muehl CFO
William J Kelly Chief Financial Officer
James Rusche Senior Vice President, Res & Development
Daniel Witt Vice President, Business Development
Howard Benjamin Vice President, Business Development
Laura Whitehouse Pew Vice President, Market Development
Stephen Tingley Vice President, Bioprocessing Business Development
Beth Gunning Director, HR
Earl Webb Henry MD Medical Director, Inventiv Clinical Solutions
Laura Whitehouse Senior Director, Market Development
Melissa M Payer Sales and Marketing Associate

Board of Directors

Name (plus bio) Position
Alexander Rich Co-Founder and Chairman of the Board
Thomas F Ryan Chairman
Alfred L Goldberg Board of Directors
Karen A. Dawes Board of Directors
Robert J. Hennessey Board of Directors

Organization Position Status
Repligen Corporation President, Chief Executive Officer and Director Current
Repligen Corporation Board of Directors Former

Organization Position Status
Repligen Corporation CFO Current

William J. Kelly joined Repligen in March 2008 as Vice President, Finance and Administration. Prior to joining Repligen, Mr. Kelly worked for Haemonetics Corporation, a medical device manufacturer, where he held the positions of Corporate Controller from 2005 to 2008 and Assistant Corporate Controller from 2001 to 2005. From 2000 to 2001, Mr. Kelly was Corporate Controller for SiteScape Corporation. Mr. Kelly is a Certified Public Accountant and previously worked for Deloitte and Touche LLP, most recently as audit manager, as well as Ernst & Young LLP. Mr. Kelly holds a B.A. in psychology from the College of the Holy Cross and an MS/MBA from Northeastern University.

Organization Position Status
Repligen Corporation Chief Financial Officer Current
Repligen Corporation Vice President Finance and Administration Current
McCarthy & Kelly Llp Partner Current
American Association for Justice Board of Directors Current
Sitescape, Inc. Corporate Controller Former
Haemonetics Corporation Former
Ground Zero Former
Northeastern University MS Former
College of the Holy Cross B.A. In Psychology Former
Brooklyn Law School Former

Organization Position Status
Repligen Corporation Senior Vice President, Res & Development Current
Repligen Corporation Vice President, Research and Development Current
University of Florida Ph.D. In Immunology Former
University of Wisconsin-La Crosse B.S. In Microbiology Former

Organization Position Status
Repligen Corporation Vice President, Business Development Current
University of Vermont Ph.D. In Biochemistry Former

Organization Position Status
Repligen Corporation Vice President, Business Development Current

Organization Position Status
Repligen Corporation Vice President, Market Development Current

Organization Position Status
Repligen Corporation Vice President, Bioprocessing Business Development Current

Organization Position Status
Repligen Corporation Director, HR Current
Repligen Corporation Director, HR Former

Organization Position Status
Clinical Solutions Senior Vice President, Medical Affairs Current
Inventiv Clinical Solutions, LLC Senior Vice President, Medical Affairs Current
Repligen Corporation Medical Director, Inventiv Clinical Solutions Current
Hhi Clinical Research & Statistical Services Medical Director Current
Repligen Corporation Board of Directors Current
Cephalon, Inc. Senior Vice President and Head, Worldwide Clinical Research & Regulatory Affairs Former
Guilford Pharmaceuticals, Inc. Vice President, Clinical Research Former
Inventiv Clinical Solutions, LLC Medical Director, Inventiv Clinical Solutions Former
Pfizer Inc. Senior Associate Director, Clinical Research Former
University of Chicago M.D. Former
University of Illinois B.S. In Chemistry Former

Organization Position Status
Repligen Corporation Senior Director, Market Development Current
Repligen Corporation Senior Director, Market Development Former

Organization Position Status
Repligen Corporation Sales and Marketing Associate Current

Dr. Rich is a founder of Alkermes and has been a director of Alkermes since 1987. Dr. Rich has been a professor at the Massachusetts Institute of Technology since 1958, and is the William Thompson Sedgwick Professor of Biophysics and Biochemistry. Dr. Rich earned both an A.B. (magna cum laude) and an M.D. (cum laude) from Harvard University. Dr. Rich is a member of the National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. Dr. Rich is Co-Chairman of the Board of Directors of Repligen Corporation, Inc. and a member of the Board of Directors for Profectus Biosciences, Inc.

Organization Position Status
Alkermes, Inc. Founder Current
Repligen Corporation Co-Founder and Chairman of the Board Current
Repligen Corporation Board of Directors Current
U.S. Genomics, Inc. Board of Directors Current
Alkermes, Inc. Director Current
Puramatrix Board of Directors Current
Profectus Biosciences, Inc. Board of Directors Current
National Academy of Sciences Board of Directors Current
American Philosophical Society Board of Directors Current
National Academy of Sciences Member Current
Harvard Medical School M.D. Former
Harvard University M.D. Former
Harvard College A.B. Former
Harvard University A.B. Former
U.S. Genomics, Inc. member Former

Organization Position Status
New York Independent System Operator, Inc. Current
Repligen Corporation Chairman Current
Repligen Corporation Board of Directors Current
Kidder, Peabody & Co. Chief Executive Officer Former
The American Stock Exchange LLC President Former
The American Stock Exchange LLC Chief Operating Officer Former
The Boston Stock Exchange Inc. Vice President of Business Development Former
Boston College trustee Former
Kidder, Peabody & Co. Chairman of the Board Former
NYSE Group, Inc. Chairman Former
Boston College BS, BA degree Former
NYSE Group, Inc. member Former

Alfred Goldberg, Ph.D., Professor of Cell Biology, Harvard Medical School. Dr. Goldberg's research focuses on the mechanisms, regulation and physiological importance of protein breakdown in animal and bacterial cells. He has contributed many fundamental discoveries about the ubiquitin proteasome pathway and its importance in immune surveillance. He has consulted widely in the pharmaceutical and biotechnology industries and has served on the Scientific Advisory Boards of Biogen, Tanox and ProScript, as well as on the editorial board of several major journals of biochemistry and physiology. Among his honors are the 1998 Novartis-Dew Award for biomedical research, the 2004 Ochoa Award from New York University and the 2005 election to the American Academy of Arts and Sciences. Dr. Goldberg was educated at Harvard College, Cambridge University and Harvard Medical School and received his Ph.D. from Harvard University.

Organization Position Status
Point Therapeutics Professor of Cell Biology, Harvard Medical School Current
Harvard Medical School Professor of Cell Biology Current
Repligen Corporation Board of Directors Current
ArQule, Inc. Board of Directors Current
Mindset Biopharmaceuticals Ltd. Board of Directors Current
Proteologics, Ltd Board of Directors Current
Santhera Pharmaceuticals AG Board of Directors Current
Biogen, Inc. Board of Directors Former
Proscript Board of Directors Former
Harvard University Ph.D. Former
Harvard Medical School Ph.D Former
Harvard College Former
Cambridge University Former

Organization Position Status
ESP Pharma, Inc. Current
PDL BioPharma, Inc. Chairman Current
Repligen Corporation Board of Directors Current
Depomed, Inc. Board of Directors Current
Genetics Institute, Inc. Vice President, Commercial Operations Former
Pfizer Inc. Vice President Former
Bayer Corporation Former
Harvard Business School MBA degree Former
Simmons College degrees in English Former

Organization Position Status
Repligen Corporation Board of Directors Current

Executive News

  • Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results

    Pharma Live - 6/04/09 - View Story

  • Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results

    PR Newswire - 6/04/09 - View Story

advertisement
     RGEN $3.79 +0.03 (0.80% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 90,060
Shares Outstanding 30.76M
Market Cap 116.6M
Year High 5.85
Year Low 3.54
Earnings Per Share -0.16
P/E Ratio -23.69
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Presented by American Express